Compare DexCom, Inc. (DXCM) vs Honest Company Inc (HNST) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

HNST trades at $3.93, down 0.76% with a mixed technical picture showing bullish moving averages but overbought RSI signals. The company reported Q1 2026 EPS of $0.01, meeting expectations, but maintains negative profitability with a -5.39% net margin. Revenue declined to $371.32M in 2025 from $378M in 2024, though operating cash flow improved to $15.12M. Analyst sentiment is cautious with 30% buy ratings amid ongoing profitability challenges.

The outlook remains challenging with persistent net losses and revenue volatility creating headwinds for shareholder value. Investment opportunity exists if margin improvements continue, but risks include competitive pressures and failure to achieve sustained profitability. The stock's elevated P/E ratio of 48.83 suggests high expectations that must be met with improved earnings performance.